Prognostic Value of Tumor Budding for Early Breast Cancer
- PMID: 38001907
- PMCID: PMC10669365
- DOI: 10.3390/biomedicines11112906
Prognostic Value of Tumor Budding for Early Breast Cancer
Abstract
Background: Tumor budding (TB) is a dynamic process associated with the epithelial-mesenchymal transition and a well-established prognostic biomarker for colorectal cancer. As part of the tumor microenvironment, tumor buds demonstrate increased cell motility and invasiveness. Current evidence demonstrates that high levels of TB correlate with disease progression and worst outcomes across different solid tumors. Our work aims to demonstrate the clinical applicability of TB analysis and its utility as a prognostic factor for patients with early breast cancer (EBC).
Methods: Retrospective, single-center, observational study, enrolling patients with EBC diagnosed in a Portuguese hospital between 2014 and 2015. TB classification was performed according to the International Tumor Budding Conference 2016 guidelines.
Results: A statistically significant relation was found between higher TB score and aggressive clinicopathological features (angiolymphatic/perineural invasion-p < 0.001; tumor size-p = 0.012; nuclear grading-p < 0.001; and Ki-67 index-p = 0.011), higher number of relapses (p < 0.001), and short disease-free survival (DFS) (p < 0.001).
Conclusion: We demonstrate that high TB correlates with shorter DFS and aggressive clinicopathological features used in daily practice to decide on the benefit of chemotherapy for EBC. TB represents a needed prognostic biomarker for EBC, comprising a new factor to be considered in the adjuvant decision-making process by identifying patients at a high risk of relapse and with higher benefit on treatment intensification. Clinical trials incorporating TB are needed to validate its prognostic impact.
Keywords: biomarker; early breast cancer; epithelial–mesenchymal transition; tumor budding.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference.Histopathology. 2020 Feb;76(3):433-446. doi: 10.1111/his.13997. Epub 2019 Dec 1. Histopathology. 2020. PMID: 31538348
-
Prognostic value of tumor budding in gallbladder cancer: application of the International Tumor Budding Consensus Conference scoring system.Virchows Arch. 2021 Jun;478(6):1071-1078. doi: 10.1007/s00428-020-03012-2. Epub 2021 Jan 4. Virchows Arch. 2021. PMID: 33398430
-
Breast Cancer Classification Based on Tumor Budding and Stem Cell-Related Signatures Facilitate Prognosis Evaluation.Front Oncol. 2022 Jan 10;11:818869. doi: 10.3389/fonc.2021.818869. eCollection 2021. Front Oncol. 2022. PMID: 35083162 Free PMC article.
-
Tumor Budding as a Marker for Poor Prognosis and Epithelial-Mesenchymal Transition in Lung Cancer: A Systematic Review and Meta-Analysis.Front Oncol. 2022 Jun 2;12:828999. doi: 10.3389/fonc.2022.828999. eCollection 2022. Front Oncol. 2022. PMID: 35719992 Free PMC article.
-
Tumour budding is a novel marker in breast cancer: the clinical application and future prospects.Ann Med. 2022 Dec;54(1):1303-1312. doi: 10.1080/07853890.2022.2070272. Ann Med. 2022. PMID: 35535687 Free PMC article. Review.
Cited by
-
Tumour Budding with Epithelial Mesenchymal Transition Markers - A Novel Prognostic Tool for Breast Carcinoma.J Midlife Health. 2025 Apr-Jun;16(2):186-191. doi: 10.4103/jmh.jmh_77_25. Epub 2025 Jun 23. J Midlife Health. 2025. PMID: 40636838 Free PMC article.
-
The relationship between tumor budding and survival of patients with breast cancer: A meta-analysis.Biomol Biomed. 2024 Oct 17;24(6):1546-1558. doi: 10.17305/bb.2024.11103. Biomol Biomed. 2024. PMID: 39319896 Free PMC article.
-
Study of tumor budding and its association with clinicopathological parameters in breast carcinoma.Rev Assoc Med Bras (1992). 2024 Aug 16;70(7):e20240173. doi: 10.1590/1806-9282.20240173. eCollection 2024. Rev Assoc Med Bras (1992). 2024. PMID: 39166665 Free PMC article.
-
Prognostic Evaluation of Piezo2 Channels in Mammary Gland Carcinoma.Cancers (Basel). 2024 Jun 29;16(13):2413. doi: 10.3390/cancers16132413. Cancers (Basel). 2024. PMID: 39001475 Free PMC article.
-
Tumour budding in invasive ductal breast carcinomas: correlation with clinicopathological prognostic parameters and hormone receptor status.Pathol Oncol Res. 2025 Feb 12;31:1611983. doi: 10.3389/pore.2025.1611983. eCollection 2025. Pathol Oncol Res. 2025. PMID: 40012857 Free PMC article.
References
-
- Al-Dewik N.I., Younes S.N., Essa M.M., Pathak S., Qoronfleh M.W. Making Biomarkers Relevant to Healthcare Innovation and Precision Medicine. Processes. 2022;10:1107. doi: 10.3390/pr10061107. - DOI
LinkOut - more resources
Full Text Sources
Research Materials